“Last Month in Tweets” was on again, off again in 2016. Apologies, we’ll be more consistent with monthly updates across the board in 2017. For now, let’s relive the best moments of 2016 at Perlara!
Although I wasn’t able to announce it publicly for several months, we learned in the first week of January that we’d been accepted into YC’s Winter 2016 batch. We were still Perlstein Lab aka PLab at the time, as summarized in this feature in Popular Science:
— Perlara PBC (@PerlaraPBC) January 12, 2016
As committed as we are to Open Science, we’re equally committed to Open Finances. In other words, it’s not enough to blog and tweet about research in real-time. You can’t have reproducibility and accountability without knowing the financial data behind the scientific data. For example, this series of burn rate posts penned by our virtual CFO Tom Ruginis (CEO @ HappiLabs):
— Perlara PBC (@PerlaraPBC) February 23, 2016
Our average monthly burn in:
2014 = $96,741
2015 = $129,869 (+34%)
2016 = $169,362 (+30%) pic.twitter.com/tGgTczq57Y
— Perlara PBC (@PerlaraPBC) December 15, 2016
— Perlara PBC (@PerlaraPBC) December 14, 2016
The first momentous news of the year as I alluded to above was our acceptance into YC, which changed the trajectory of the company (as I blogged here):
Perlstein Lab (YC W16) Automates Drug Discovery for Rare Diseases https://t.co/7F2OYzdeQs
— Y Combinator (@ycombinator) March 21, 2016
We continued to blog about our Niemann-Pick C lead program and lead compound PERL101. Look for Part 4 to drop in early January. Much more detail on what PerlQuest joint drug discovery partnerships are in the new year, too. For now think about the PERL101 blogs (Part 1, Part 2, Part 3) as the first PerlQuest in progress.
ICYMI the ongoing drug discovery journey of PERL101, a lead compound for Niemann-Pick C https://t.co/RkzfSI6tKc
— Perlara PBC (@PerlaraPBC) April 16, 2016
This is drug discovery and early development, unmasked: From primary screen to mouse validation, Part 3 https://t.co/Z4nBpaDtM0
— Jeb Keiper (@JebKeiper) July 22, 2016
The core tenet of our company culture is diversity, reflecting the diversity of rare disease families. In 2016 our headcount grew from 6 to 8. We look forward to further expansion in 2017.
Welcome to the team, @FebaSusanSam! The majority of PLab scientists are women. How many biotech startups can say that?
— Perlara PBC (@PerlaraPBC) May 3, 2016
Thrilled to announce the newest (and 8th) member of PLab: Hillary Tsang! #TeamNematode
— Perlara PBC (@PerlaraPBC) August 29, 2016
Perlara attended its third Parseghian conference. The meeting returned home to Arizona. By next year’s meeting we’ll know whether the PERL101 chemical series is on a pathway toward IND. We’ll also have made progress on several other LSDs by June 2017.
The Ara Parseghian Medical Research Foundation 2016 annual meeting is officially underway in Tucson AZ. #APMRF16
— Perlara PBC (@PerlaraPBC) June 5, 2016
Summer was high season for science communication. We attended several conferences and took the blog:
My blog on the rare disease MLIV, and how model organisms can help. https://t.co/aZmhfpdPwF
— Tom Hartl (@hartl_tom) July 1, 2016
— Nina DiPrimio (@NinaDiPrimio) July 6, 2016
Thanks everyone who came by the poster. And feel free to contact me if you want to know more about @PerlsteinLab and our science!! #TAGC16
— Tamy Portillo (@Tamy_Portillo) July 16, 2016
NGLY1 mutant flies are hypersensitive to the organic solvent DMSO (but we don't understand why) https://t.co/EyVRSghhFm
— Perlara PBC (@PerlaraPBC) August 10, 2016
The second big news of the year was our rebrand from PLab to Perlara. We announced our name change and new site at Global Genes:
— Perlara PBC (@PerlaraPBC) September 22, 2016
— Stephanie Fischer (@RarePOV) September 23, 2016
Unprecedented model for public involvement in new drug R&D – really exciting! https://t.co/g5kvTflwuD
— Frank David (@Frank_S_David) September 25, 2016
In October, two years of hard work came together in the form of a validating deal with NIBR.
— Lisa Jarvis (@lisamjarvis) October 19, 2016
Thrilled to collaborate with Perlara/@eperste on organism-based screening; chembio meets lysosomal storage diseases https://t.co/Y6LQtl9EeX
— Jay Bradner, M.D. (@jaybradner) October 19, 2016
— Novartis Science (@NovartisScience) October 19, 2016
— Nature News&Comment (@NatureNews) November 1, 2016
Normally things slow down after Thanksgiving, but that’s when the last bout of good news streamed in. In fact, we were working till yesterday afternoon to close our third partnership – that’s 3 in as many months.
We reached an important company milestone today: first revenue.
— Perlara PBC (@PerlaraPBC) November 28, 2016
We closed our first PerlQuest partnership this month. PR announcement and PerlQuest FAQ coming soon. pic.twitter.com/RSQ8gKACpj
— Perlara PBC (@PerlaraPBC) December 1, 2016
We’re putting the finishing touches on a PerlQuest FAQ now, and it will go live in less than two weeks. Thanks for taking a quick stroll down memory lane. Onward 2017!